Clinical trial
Eflornithine in Treating Patients With Bladder Cancer
NCT00003814 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003814 |
|---|---|
| Title | Eflornithine in Treating Patients With Bladder Cancer |
| Official title | Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | eflornithine |
| Enrollment | 450 |
| Start date | Feb 1, 1999 |
| Completion | May 1, 2007 |
| First posted | Feb 20, 2004 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: